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Abstract
Birt-Hogg-Dube´ syndrome is associated with an increased risk for renal cell carcinoma. Sur-
veillance is recommended, but the optimal imaging method and screening interval remain to
be defined. The main aim of our study was to evaluate the outcomes of RCC surveillance to
get insight in the safety of annual US in these patients. Surveillance data and medical rec-
ords of 199 patients with Birt-Hogg-Dube´ syndrome were collected retrospectively using
medical files and a questionnaire. These patients were diagnosed in two Dutch hospitals
and data were collected until June 2014. A first screening for renal cell carcinoma was per-
formed in 172/199 patients (86%). Follow-up data were available from 121 patients. The
mean follow-up period per patient was 4.2 years. Of the patients known to be under surveil-
lance, 83% was screened at least annually and 94% at least every two years. Thirty-eight
renal cell carcinomas had occurred in 23 patients. The mean age at diagnosis of the first
tumour was 51. Eighteen tumours were visualized by ultrasound. Nine small tumours (7–27
mm) were visible on MRI or CT and not detected using ultrasound. Our data indicate that
compliance to renal screening is relatively high. Furthermore, ultrasound might be a sensi-
tive, cheap and widely available alternative for MRI or part of the MRIs for detecting clinically
relevant renal tumours in BHD patients,but the limitations should be considered carefully.
Data from larger cohorts are necessary to confirm these observations.
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Introduction
Birt-Hogg-Dube´ syndrome (BHD, OMIM #315150) is an autosomal dominant condition
caused by germline mutations in the FLCN gene encoding folliculin and is characterized by
fibrofolliculomas, lung cysts, spontaneous pneumothorax and renal cell carcinoma (RCC) [1].
Around 3–5% of all RCCs is estimated to have a hereditary cause [2]. Hereditary RCCs differ
from the far more common sporadic form in several aspects. Hereditary tumours often present
at a relatively younger age, are often multifocal and/ or bilateral and may have a characteristic
histology. In addition, they may be associated with recognizable syndromic features besides
RCC. The family history may be positive for RCC or for associated syndromic clinical features.
In patients with BHD, the prevalence of RCC is estimated to be 16–34% with a mean age at
diagnosis of 50 years [3–6]. The most commonly reported histological subtypes of BHD associ-
ated renal tumours is hybrid oncocytic/chromophobe renal cell carcinoma. However, other
subtypes also occur [3, 5–10]. Renal surveillance in BHD patients has been recommended
from age 20, preferably by annual MRI (Magnetic Resonance Imaging) [11]. This is based on
the high sensitivity and the lack of radiation exposure of MRI. However, its availability and
costs may be limitations in clinical practice. To our knowledge, evaluation of renal screening
in BHD patients has not been previously performed. To gain insight in the optimal screening
regimens in rare disorders, it is crucial to study available data of patient cohorts. The recom-
mended screening program in the Dutch hospitals has changed over the years based on expert
opinion. A first screening in BHD patients has mostly consisted of both MRI and ultrasound
(US). All patients were advised to perform annual follow-up. Dependent on the moment in
time and the hospital where the diagnosis was established, the follow-up consisted of MRI, US,
CT-scan (computed tomography) or a combination of these. The main aim of the study was
twofold: to evaluate the outcomes of RCC surveillance to get insight in the safety of annual US
and to evaluate the compliance to RCC surveillance.
Materials and methods
Data of 199 BHD patients diagnosed with BHD at the VU University Medical Center and The
Netherlands Cancer Institute were collected. Data were collected from the first screening until
June 2014. The collection of family data and the methods of mutation analysis have been out-
lined in previous publications [3, 12]. Mutation testing and family counselling took place from
2004, after discovery of the FLCN gene. In all 199 patients, the diagnosis was confirmed by
FLCN mutation testing. Our cohort includes both symptomatic index patients and healthy
family members identified after pre-symptomatic DNA testing. Screening data and data on
RCC were retrieved from the local medical files. In addition, the researchers sent a question-
naire on surveillance performed in other medical institutions to all patients in 2014. The
patients were asked for the dates of screening, the imaging modality and findings and they
were asked to give consent to collect these medical data. Sixty-six patients returned the ques-
tionnaire. The Medical Ethics Review Committee of the VUmc confirmed that the Medical
Research Involving Human Subjects Acts (WMO) did not apply to this study. Official approval
of the study was therefore not required. Patient data were anonymized.
For evaluation of compliance with surveillance, we assessed initial screening and follow-up
screening data. Initial screening was defined as the first renal imaging performed in a patient
after being diagnosed with BHD. For all patients who had initial screening, this took place
within maximum one year after the genetic diagnosis of BHD. Patients diagnosed with (symp-
tomatic) RCC before the diagnosis of BHD was established, were not considered to have had
initial screening, but only follow-up screening. Follow-up was defined as all screening that
took place after the initial screening or after the RCC diagnosis. Patients were included in the
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analysis of follow-up, if follow-up data until maximum 1.5 years before the end of the study
(June 2014) or 1.5 years before death were complete.
Results
Screening compliance
Fig 1 shows a flowchart of the screening performed in the cohort. For 24 of 199 patients, we
had no screening data at all. Some of these patients declined screening because of, for example,
old age or having metastatic cancer. For 13 of these 24 patients, it was unknown whether
screening was performed. They did not return the questionnaire and were not screened in one
of the two hospitals participating in this study.
All patients with initial screening data (n = 172) underwent initial screening within 1 year
after being diagnosed with BHD. Follow-up data could not be collected for 54 patients. In 16
of them, BHD had been diagnosed recently, so no follow-up was necessary yet. The other 38
patients did not return the questionnaire and were not screened in one of the two hospitals
participating in this study. They might however undergo screening via their general practi-
tioner in a regional hospital.
Fig 1. Screening data of 199 BHD patients.
https://doi.org/10.1371/journal.pone.0212952.g001
Screening in Birt-Hogg-Dube´ syndrome
PLOS ONE | https://doi.org/10.1371/journal.pone.0212952 March 7, 2019 3 / 9
The mean age at initial screening was 50 (median 51, range 20–83). The data of initial and
follow-up screening data are shown in Table 1. The mean follow-up period was 4.2 years
(median 4; range 1–9). Most of the missed screening moments occurred in the first year of fol-
low-up (13%). From the second to ninth year approximately 3–9% of patients per year missed
a screening moment. The majority of patients (101/121, 83%) was screened at least once a year
and missed no screening moment, 114/121 patients (94%) were screened at least once every
two years, so they did not miss more than one successive screening moment in Table 1.
RCC
A total of 23 patients (13 male, 10 female) had been diagnosed with RCC. Table 2 shows
tumour and patient characteristics. The mean age at diagnosis of the first RCC was 51 (range
24–77). In total, 38 tumours were detected in the 23 patients. Of one tumour no data was avail-
able since the treatment took place 34 years ago. Tthis tumour is not mentioned in the table.
The histology was available for 29 tumours and was either chromophobe (44.8%), clearcell
(24.1%), mixed chromophobe/clearcell (10.3%), papillary (6.9%), hybrid oncocytic/chromo-
phobe (3.4%), sarcomatoid (3.4%), mixed chromophobe/clearcell/papillary (3.4%) or unclassi-
fied (3.4%). Histology was unavailable in the four untreated tumours, in three tumours treated
with cryo-ablation or RFA, and the histology reports of one patient were unavailable due to
missing consent.
An ultrasound (US) was performed in 18 of the 38 tumours around the time of diagnosis.
Nine tumours, sized 20 to 120 mm, were detected by US. Nine tumours, sized 7 to 27 mm,
were seen on MRI or CT but not seen with US. The histology of the tumours not seen by US
was either chromophobe (n = 4), clearcell (n = 1), mixed chromophobe/clearcell (n = 1) or
unknown (n = 3, due to RFA treatment or no data). Four patients died from RCC, they all
were diagnosed with metastatic before the diagnosis of BHD. One patient died from metastasis
of a malignancy unrelated to BHD. No patients were diagnosed with metastasized RCC during
follow-up.
Discussion
To gain insight in optimal screening regimens in rare genetic cancer predisposition syn-
dromes, it is crucial to study available patient cohort data. We aimed to collect data from 199
Dutch patients diagnosed with BHD in two Dutch centers. The recommended screening pro-
gram in the Netherlands has changed over the years and may vary between hospitals. Initial
screening in BHD patients often consisted of both MRI and US followed by annual US.
Table 1. Overview of number of patients that underwent initial and follow-up screening per year.
Initial screening Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9
Total number of patients in follow-up 172 121 105 91 72 49 33 28 17 10
MRI + US 120 (69.8%) 18 17 14 12 11 7 5 2 0
US 9 (5.2%) 61 57 46 43 30 17 12 10 10
MRI 31(18.0%) 3 5 7 2 0 2 3 1 0
Other1 9 (5.2%) 4 1 3 1 1 0 1 1 0
Technique unknown2 3 (1.7%) 19 20 14 9 4 4 6 2 0
No screening (%) NA 16 (13.2%) 5 (4.8%) 7 (7.7%) 5 (6.9%) 3 (6.1%) 3 (9.1%) 1 (3.6%) 1 (5.9%) 0 (0.0%)
1 CT, CT and US or CT and MRI
2 Self-reported screening with questionnaire in which technique was not mentioned.
NA: not applicable
https://doi.org/10.1371/journal.pone.0212952.t001
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Table 2. Detected RCCs: Tumour and patient characteristics.
Sex Age at
dx
Tumour size
(mm)
Moment of
dx
Symptoms Detected with Missed with Last screening before
dx
Duration of follow-up after last
tumour
F 74 40 (PA) <BHD AS CT NA NA 7 years FU
60 (PA) <BHD CT
20 (PA) <BHD CT
11 (PA) <BHD CT
M 51 69 <BHD S CT NA NA Metastasis at diagnosis, died
M 56 120 <BHD S CT + US NA NA Metastasis at diagnosis, died
M 56 51 (PA) <BHD AS CT NA NA Died due to metastasis of
23 (PA) <BHD CT other malignancy
17 (PA) <BHD CT
F 25 110 (PA) <BHD S CT + US NA NA 21 years FU
M 42 14 <BHD AS CT NA NA 2 years FU
81 <BHD CT Current size unknown
M 69 55 (multifocal) <BHD AS CT NA NA Unknown
15–20
(multifocal)
<BHD
F 40 30 <BHD U MRI + US NA NA 10 years FU
M 24 70 <BHD U MRI+US NA NA Metastasis at diagnosis, died
M 28 110 <BHD U MRI + US NA NA Metastasis at diagnosis, died
F 55 27 Initial AS MRI US (2 mo. earlier) NA 3 years FU
M 69 31 Initial U MRI NA NA 3 years (tumour is 9 mm after 3
years)
M 31 18 Initial AS MRI (+2nd
US)
US (same day) NA 3 years FU
F 53 19 Initial S CT NA NA 2 years FU
F 64 16 Initial AS MRI US (6 weeks earlier) NA 4 years FU
71 Initial MRI US (6 weeks earlier) NA Current size unknown
51 (6 mo. later) Initial MRI NA NA Current size unknown
M 76 15 Initial AS CT US (3 weeks earlier) NA 4 years FU
20 Initial CT + US NA
22 Initial CT US (3 weeks earlier)
M 43 10 Initial AS MRI + CT NA 6 mo bef: US NA
14 Initial NA
F 49 17 Initial AS MRI + CT NA NA NA
M 33 90 Initial U MRI +US NA NA 2 years FU (after last tumour)
35 13 FU MRI US (same day) 1 yr. bef: MRI+US
39 30 FU MRI NA 6 mo. bef: US
F 77 11 FU AS CT US (3 weeks earlier) 6 mo. bef: US 1 year FU
M 29 22 FU U MRI + US NA 1 yr. bef: MRI+US NA
F 60 50 FU U US NA Unknown 5 years FU
F 62 14 FU U MRI US (interval
unknown)
1 yr. bef: MRI+US NA
1 Tumour was not treated and is in follow-up.
Mo.: months; yr.: years; dx: diagnosis. Sex: F ; female, M; male. Tumour size: reported as size on imaging when available. In case of both US and CT/MRI is size on CT
or MRI reported. In case of both CT and MRI, the largest described size is reported. PA; size measured by pathologist, no imaging size available. Moment of diagnosis:
< BHD; diagnosis of RCC made before the diagnosis of BHD, FU; tumour diagnosed at follow-up, initial; tumour diagnosed at initial screening. Symptoms: U;
unknown, AS; asymptomatic, S: symptomatic. Outcome: NA; not applicable
https://doi.org/10.1371/journal.pone.0212952.t002
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Currently, initial screening usually consists of MRI only. The goal of initial screening by both
MRI and US was to gain more insight in the optimal screening technique, since there are no
evidence based guidelines for screening in BHD patients. The change to MRI only was based
on expert opinion. As expected, the data show that the majority of performed initial screening
consisted of both MRI and US (70%) and that the majority (53%) of follow-up screening con-
sisted of US only.
In some patients annual imaging was performed in one of the two hospitals participating in
this study. However, the majority of patients were screened in local or regional hospitals. This
makes it difficult to remain up to date on the screening compliance and outcomes. Using ques-
tionnaires, we tried to collect these data of as many patients as possible. The presented data
show that at least 86% (172/199) of the BHD patients underwent initial screening. Excluding
patients with a diagnosis of RCC before the diagnosis of BHD, patients with metastatic cancer
before the diagnosis of BHD and patients who underwent no screening because of old age, this
increases to 93% (172/185). At least 61% (121/199) of the BHD patients performed follow-up
screening. Excluding patients who underwent no screening because of old age, patients with
metastatic cancer before the diagnosis of BHD and patients with a recent diagnosis of BHD,
this increases to 70% (121/174).
Our cohort of patients with BHD participating in the screening program (n = 121) is highly
compliant to the recommended screening regimen (83%). The fact that the most missed
screening moments were in the first year after initial screening, might be due to less awareness
of the patients own responsibility for organizing follow-up screening via their general practi-
tioner. This might be improved by addressing this during genetic counseling or at initial
screening. The exact number of patients declining screening and their reasons to do so remain
unclear. The screening compliance is comparable to that reported in patients with Lynch syn-
drome (87%) [13].
The biological behaviour of RCC in BHD is reported to be indolent and metastases rarely
occur at smaller tumour sizes. Taking into account the relatively high frequency of multiple or
bilateral tumours, parenchymal sparing surgical treatment is important in patients with a
hereditary predisposition for renal carcinoma [14, 15]. The aims of the treatment are local
tumour control, preservation of renal function and prevention of metastatic disease. Nephron
sparing treatment is often possible, since these slow growing tumours are often discovered at a
small size. The ‘3 cm rule’, which recommends surgical intervention when the (largest) lesion
exceeds 3 cm in diameter, is often applied to patients with Von Hippel Lindau disease, heredi-
tary papillary RCC and BHD [2, 14, 16, 17]. In a previous study of 49 patients with hereditary
RCC, no metastatic disease was reported in more than 10 years follow-up when adhering to
the ‘3 cm rule’. It must be noted that in this study only 1 patient with BHD was included [15].
In our group of 23 BHD patients diagnosed with RCC, most patients had local treatment. The
treatment of tumours smaller than 3 cm was possibly performed at the request of the patient
due to anxiety. In addition, the increasing availability of radiofrequency ablation and cryother-
apy for small tumours may have played a role in these decisions. When screening BHD
patients, it is crucial that no tumours larger than 3 cm are missed by the applied screening
technique and the screening interval must ensure that no tumours larger than 3 cm develop
during the screening interval.
The main techniques to be considered for the imaging of renal tumours are CT, MRI and
US. These imaging modalities each have their strengths and weaknesses. CT is a fast and robust
technique to display the kidneys three-dimensionally and with great anatomical detail. CT is
the gold standard for the diagnosis and staging of renal cell carcinoma [18]. Despite these qual-
ities, the use of CT for annual surveillance might lead to unacceptably high cumulative radia-
tion doses as patients would require many CT scans during their lifetime [19]. MRI is a
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technique that provides excellent soft tissue contrast without the use of radiation. It is powerful
for the detection and characterization of focal renal lesions, various RCC subtypes can be dif-
ferentiated and patency of blood vessels can be visualised without the use of intravenous con-
trast. Drawbacks of MRI are long examination times (30–45 minutes), variations in quality
and scan protocols, limited availability and high costs [17]. In some patients MRI cannot be
performed due to claustrophobia, obesity, or the presence of metallic implants. US has the
advantages of being widely available, fast, cheap and lacking ionizing radiation. However,
small renal lesions can be missed due to limited spatial resolution of US, depending on intrare-
nal location, isoechoic aspect of a lesion, obesity or obscuring bowel gas [14, 17, 20]. Further-
more US sensitivity depends on operator experience. Renal imaging with 1–3 year intervals
has been proposed for BHD patients without renal lesions on initial imaging [11, 14, 21].
Using US, 9 of 18 tumours were missed in our cohort. All missed tumours were smaller
than 3 cm (largest 27 mm). The histology of the missed tumours was comparable to that of the
detectable tumours, suggesting that the histology is no major factor in the chance of missing a
tumour on US. Consistent with current literature, no metastatic disease occurred in patients
with RCC smaller than 3 cm. Our findings further emphasize the need for early diagnosis of
BHD and performing screening from age 20 onwards or from the moment BHD is diagnosed.
All 4 patients with metastatic RCC in our cohort, developed this disease before being aware of
having BHD and two of them were only in their twenties. Since most RCCs were diagnosed at
initial screening and BHD related RCCs are reported to have an indolent nature, it is likely
that part of the tumours in our cohort could have been detected at an earlier time, if screening
would have been performed.
Based on the findings in our cohort, annual US may be a safe and less expensive alternative
for MRI, since only tumours smaller than 3 cm were missed on US. However, there are multi-
ple disadvantages of this approach. First, early detection of a renal mass is likely to motivate
patients to undergo repeated follow-up screening whereas false negative outcomes might lead
to complacency. Second, if patients are not compliant to the annual surveillance, a small
tumour might grow beyond 3 cm in the interval between imaging. Third, a tumour just under
3 cm might be missed with US and if it happens to grow relatively fast, might grow beyond 3
cm within a year. The final choice for MRI and US might also depend on local factors. The
costs for individual patients and for the healthcare system of MRI and US might differ between
countries. In the current Dutch situation, annual MRI is a far more expensive for the patient
than annual US. The high costs of MRI might discourage patients from undergoing repeated
screening. The final decision on the optimal surveillance should be made based on the above
mentioned limitations and might differ between countries and even between patients. A com-
promise between the choice for MRI or US, might be annual surveillance with alternating MRI
and US.
Conclusions
Our main findings are that initial screening was performed in the vast majority of patients and
that 85% of patients in the screened cohort was compliant with annual renal imaging. Ultra-
sound might be a sensitive, cheap and widely available alternative for MRI or part of the MRIs
for detecting renal lesions larger than 3 cm in BHD patients. However, US has limitations and
all of them should be carefully considered when determining the optimal surveillance. It might
be important to give more attention to the recommended screening program, especially to the
first follow-up moment after initial screening. Further studies are needed to determine
whether our results for BHD patients in this study can be reproduced, preferably in a relatively
large group of patients screened both by MRI and by ultrasound.
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